Black Diamond Therapeutics reports 36% response rate for Phase 2 drug BDTX-1535 in non-small cell lung cancer trial.

Black Diamond Therapeutics Inc. has reported promising initial Phase 2 results for its drug candidate BDTX-1535, targeting relapsed/refractory EGFR-mutant non-small cell lung cancer (NSCLC). Among 22 evaluable patients, the objective response rate was 36%, with most adverse events being mild.

September 23, 2024
4 Articles

Further Reading